Oxford BioDynamics (LON:OBD) Shares Down 1.8% – What’s Next?

Oxford BioDynamics Plc (LON:OBD) was down 1.8% on Tuesday . The stock traded as low as GBX 0.08 and last traded at GBX 0.11. Approximately 29,929,361 shares were traded during mid-day trading, an increase of 80% from the average session volume of 16,632,014 shares. The stock had previously closed at GBX 0.11.

Oxford BioDynamics Trading Down 0.9%

The firm has a market cap of £4.76 million, a price-to-earnings ratio of -0.55 and a beta of 0.42. The company has a debt-to-equity ratio of 131.61, a current ratio of 2.01 and a quick ratio of 2.80. The business has a 50-day moving average of GBX 0.17 and a 200-day moving average of GBX 0.22.

Oxford BioDynamics (LON:OBD) last issued its quarterly earnings results on Tuesday, June 30th. The biotechnology company reported GBX (0.10) EPS for the quarter. Oxford BioDynamics had a negative net margin of 825.61% and a negative return on equity of 451.74%.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.